Your Health, We Care
Release date: 2024-08-05 15:44:58 Recommended: 166
Sotorasib, an innovative medication targeting specific genetic mutations in non-small cell lung cancer (NSCLC), has emerged as a novel option for treating this disease owing to its unique efficacy and relatively low side effects.
In foreign markets, there are two versions of Sotorasib available - the original drug and the generic version, each with differing prices.
The original Sotorasib manufactured by Amgen in the United States is priced at approximately ¥80,155 per box for a specification of 120mg * 240 capsules. The high costs of research and development, alongside stringent patent protections, contribute to the high price of the original drug.
The generic version of Sotorasib produced by Everest Medicines, with a specification of 120mg * 56 capsules, is priced at around ¥4,900 per box. The generic version from Lucius Pharmaceuticals in Laos, also with a specification of 120mg * 56 capsules, costs approximately ¥2,850 per box. Additionally, the generic version by Boquete Pharmaceuticals in Paraguay, available in 120mg * 120 capsules, is priced at approximately ¥7,500 per box.
It is important to note that the aforementioned prices are for reference only and may vary due to factors such as regional differences, purchasing channels, and policy adjustments. Patients should seek guidance from healthcare professionals before using Sotorasib and avoid self-medication. Prior to use, patients should also be aware of specific drug requirements for special populations to prevent misuse.
Special populations to consider when using Sotorasib include pregnant women, lactating women, the elderly, and children. It is imperative for these groups to strictly adhere to physicians' advice, undergo regular check-ups, and closely monitor their physical conditions during the treatment process.
Pregnant women should exercise caution when using Sotorasib and follow medical advice regarding dosage. Lactating women are advised to avoid breastfeeding during treatment and for one week after the last dose to minimize potential effects on infants.
Due to declining bodily functions in the elderly population, adjustments in dosage and treatment plans may be necessary when using Sotorasib based on physicians' recommendations.
The safety and efficacy of Sotorasib in pediatric patients have not been conclusively established, warranting cautious use in this population. Individualized treatment under medical supervision is advised when deemed necessary.
[warm tips] In making the decision to use Sotorasib, patients should consider their economic status, the severity of the condition, and medical advice. Adherence to prescribed medication schedules, regular monitoring, and treatment follow-ups are essential to ensure treatment efficacy and patient safety.
